Earlier on May 30, Siebert Financial CIO Mark Malek appeared on CNBC to discuss the tariff headwinds swirling around the markets and which sectors could then rise above the noise and continue to perform. The question posed to Malek was whether investors should maintain a long-term buy-and-hold strategy or become more responsive to daily headlines. Malek believes that the answer depends on the specific stocks and sectors and cannot be as straightforward.
However, he believes that sectors like tech and communications, which have driven the NASDAQ’s recent performance, are suitable for a Rip Van Winkle approach, which refers to long-term holding. He suggests that mid-to-long-term opportunities in these sectors will outweigh short-term news fluctuations and that these news cycles may even create opportunities for new investors to enter these markets.
Malek then discussed concerns about the market’s collective reliance on the AI trade, given that it appears to be the primary investment focus for many. He acknowledged this sentiment but countered that such a confluence of strong fundamentals, expanding markets, and new blue ocean opportunities is rare, occurring perhaps only 2 or 3 other times in history.
That being said, we’re here with a list of the 11 most profitable NASDAQ stocks to buy now.
An overhead view of a bustling stock exchange, with brokers and traders exchanging stocks.
Our Methodology
We sifted through the Finviz stock screener to compile a list of the top stocks with a forward P/E ratio under 15. We then selected 11 stocks with a TTM net income greater than $1 billion that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q1 2025.
Note: All data was recorded on June 13.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Most Profitable NASDAQ Stocks to Buy Now
11. Arch Capital Group Ltd. (NASDAQ:ACGL)
TTM Net Income as of June 13: $3.77 billion
Forward P/E Ratio as of June 13: 11.93
Number of Hedge Fund Holders: 46
Arch Capital Group Ltd. (NASDAQ:ACGL) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Arch Capital Group announced a strategic integration with Wilqo’s Charlie platform. This was done through the company’s subsidiary called Arch Mortgage Insurance Company (Arch MI). The partnership aims to streamline the mortgage lending process by incorporating Arch MI’s RateStar pricing directly into the Charlie platform.
The collaboration will enhance efficiency, reduce the time involved in closing mortgage applications, and facilitate faster homeownership for borrowers by consolidating previously disconnected processes. Will Vickers, Vice President of Industry Technology at Arch MI, highlighted that Arch MI is the first mortgage insurer to integrate directly with Wilqo’s Charlie platform.
Arch Capital Group’s stock price saw a 3% increase over the last quarter. The company’s total shareholder return over the past 5 years is a remarkable 180.36%. However, on an annual basis, Arch Capital underperformed both the US Insurance industry, which saw an 18.5% return, and the broader US market, which returned 11.5%.
Arch Capital Group Ltd. (NASDAQ:ACGL) provides insurance, reinsurance, and mortgage insurance products in the US, Canada, Bermuda, the UK, Europe, and Australia.
10. Huntington Bancshares Incorporated (NASDAQ:HBAN)
TTM Net Income as of June 13: $2.05 billion
Forward P/E Ratio as of June 13: 11.24
Number of Hedge Fund Holders: 47
Huntington Bancshares Incorporated (NASDAQ:HBAN) is one of the 11 most profitable NASDAQ stocks to buy now. Earlier in mid-May, Huntington Bancshares announced its expansion into Florida’s commercial banking sector. This move is part of the bank’s broader national growth strategy, following recent expansions in North Carolina, South Carolina, and Texas over the last 2 years.
Huntington’s Florida push will initially focus on providing middle-market services, with a new office established in Fort Lauderdale. To lead these efforts, Huntington has hired Josh Sheradsky as Senior Managing Director. Sheradsky brings 16 years of experience as a middle-market banker in South Florida.
Huntington’s commercial banking segment offers services to mid-sized corporate clients, such as lending, liquidity solutions, treasury management, payment services, and capital markets support. The teams adopt a relationship-based and insights-driven approach to provide holistic solutions. Additionally, the Florida team will aim to connect middle-market clients with Huntington’s other offerings, such as wealth management & investment banking.
Huntington Bancshares Incorporated (NASDAQ:HBAN) operates as the bank holding company for The Huntington National Bank, which provides commercial, consumer, and mortgage banking services.
9. eBay Inc. (NASDAQ:EBAY)
TTM Net Income as of June 13: $2.04 billion
Forward P/E Ratio as of June 13: 14.51
Number of Hedge Fund Holders: 51
eBay Inc. (NASDAQ:EBAY) is one of the 11 most profitable NASDAQ stocks to buy now. On June 4, JPMorgan analyst Doug Anmuth raised the price target on eBay to $66 from $60, while maintaining a Neutral rating on the shares. This adjustment reflects eBay’s better-than-expected Q1 2o25 earnings.
JPMorgan’s decision to revise its estimates comes from a reevaluation of broader market risks, now seeing lower recession risk, alongside anticipated relief from China tariffs for companies with direct exposure. In Q1, eBay saw its revenue increase by over 1% to $2.58 billion. Gross Merchandise Volume/GMV grew by ~2% to $18.8 billion, which marked the 4th consecutive quarter of positive GMV growth.
First-party advertising revenue also showed strong growth, increasing by 14% to $418 million. eBay generated $644 million in free cash flow and ended the quarter with $6.2 billion in cash and non-equity investments. Despite these positive results, challenges remain. Tariffs and changes to US customs requirements have introduced uncertainty for small businesses and impacted consumer confidence.
eBay Inc. (NASDAQ:EBAY) operates marketplace platforms that connect buyers and sellers in the US, the UK, China, Germany, and internationally.
8. Biogen Inc. (NASDAQ:BIIB)
TTM Net Income as of June 13: $1.48 billion
Forward P/E Ratio as of June 13: 13.07
Number of Hedge Fund Holders: 52
Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting in Barcelona, Spain.
The study showed clinical improvements in disease activity for individuals with moderate-to-severe systemic lupus erythematosus/SLE when treated with DZP in addition to standard of care/SOC. Systemic Lupus Erythematosus (SLE) is a chronic, multifactorial autoimmune disease characterized by the activation of autoreactive immune cells, leading to manifestations across various organ systems. It affects an estimated 90% of women, with symptoms typically appearing between the ages of 15-55.
The primary endpoint, which was measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment/BICLA at Week 48, showed positive results. It’s important to note that the safety and efficacy of DZP in SLE are not yet established, and it is not approved by any regulatory authority worldwide for this indication. A second Phase 3 trial, PHOENYCS FLY, is currently underway to confirm the findings from PHOENYCS GO.
Biogen Inc. (NASDAQ:BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases internationally. UCB is a global biopharmaceutical company that discovers and develops innovative medicines and solutions for severe diseases of the immune system or the CNS.
7. Expedia Group Inc. (NASDAQ:EXPE)
TTM Net Income as of June 13: $1.17 billion
Forward P/E Ratio as of June 13: 11.82
Number of Hedge Fund Holders: 54
Expedia Group Inc. (NASDAQ:EXPE) is one of the 11 most profitable NASDAQ stocks to buy now. Earlier in mid-May, Expedia Group announced advancements to its B2B technology platform, which emphasized AI-powered innovations and new API capabilities to enhance travel experiences for both partners and travelers. These updates were revealed at the company’s premier EXPLORE event.
The expansion includes new B2B APIs designed to scale Expedia Group’s Private Label Solutions. These next-gen APIs provide partners with access to expanded travel inventory and capabilities, such as a Car API offering inventory from 110+ brands across 190 countries, an Activities API with 170,000+ bookable experiences worldwide, and an Insurance API for trip protection integration.
Using GenAI, Expedia Group is redefining travel discovery with innovative traveler experiences. This includes Expedia Trip Matching, which is a first-of-its-kind feature set for beta release in June, that converts Instagram reels into personalized travel recommendations. Travelers can share reels and receive AI-generated itineraries and tips.
Expedia Group Inc. (NASDAQ:EXPE) is an online travel company in the US and internationally. The company operates through B2C, B2B, and trivago segments.
6. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
TTM Net Income as of June 13: $4.49 billion
Forward P/E Ratio as of June 13: 14.27
Number of Hedge Fund Holders: 66
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 Revolutionizing Atopic Dermatitis/RAD Conference on June 7.
The DISCOVER trial enrolled 120 subjects with AD and Fitzpatrick skin types IV-VI (defined as light brown to black skin with high melanin content). Patients aged 12 years and older received Dupixent monotherapy every 2 weeks based on weight after a loading dose. At the 24-week mark, the study met its primary endpoint: 76% of participants achieved at least a 75% improvement in overall disease severity as measured by the Eczema Area and Severity Index (EASI-75).
Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was invented using Regeneron’s VelocImmune technology and developed in collaboration with Sanofi. It is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways without being an immunosuppressant. Over 1,000,000 patients are currently being treated with Dupixent globally.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Sanofi (NASDAQ:SNY) is a healthcare company that researches, develops, manufactures, and markets therapeutic solutions.
5. Amgen Inc. (NASDAQ:AMGN)
TTM Net Income as of June 13: $5.93 billion
Forward P/E Ratio as of June 13: 14.24
Number of Hedge Fund Holders: 69
Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine.
It showed that IMDELLTRA reduced the risk of death by 40% and extended median overall survival by over 5 months compared to standard-of-care/SOC chemotherapy in patients with small cell lung cancer/SCLC who had progressed on or after one line of platinum-based chemotherapy. IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen.
It binds to DLL3, which is a protein expressed on the surface of SCLC cells in ~85-96% of patients but minimally on healthy cells, and CD3 on T-cells. This dual binding activates T-cells to specifically target and kill DLL3-expressing SCLC cells. The DeLLphi-304 trial is a global Phase 3, randomized, controlled, and open-label clinical study. It enrolled 509 patients. The results support the potential conversion of IMDELLTRA’s accelerated FDA approval, which was granted last year based on tumor response rates, into a full approval.
Amgen Inc. (NASDAQ:AMGN) discovers, develops, and manufactures human therapeutics globally.
4. Gilead Sciences Inc. (NASDAQ:GILD)
TTM Net Income as of June 13: $5.97 billion
Forward P/E Ratio as of June 13: 14.16
Number of Hedge Fund Holders: 79
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch.
The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy.
In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street’s estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts’ estimates. These results were driven by growth in the company’s core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi.
Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally.
3. Comcast Corporation (NASDAQ:CMCSA)
TTM Net Income as of June 13: $15.71 billion
Forward P/E Ratio as of June 13: 8.24
Number of Hedge Fund Holders: 81
Comcast Corporation (NASDAQ:CMCSA) is one of the 11 most profitable NASDAQ stocks to buy now. Earlier on May 28, Comcast announced the commencement of construction for its next-gen high-speed internet network across 7 counties in Indiana: Fayette, Rush, Delaware, Boone, Shelby, Morgan, and Miami. This multi-million dollar investment aims to connect over 10,000 residents and businesses in these areas and provide them with access to Comcast’s full suite of services.
The project is a joint investment in partnership with Indiana’s Next Level Connections Broadband Grant Program, which has allocated $350 million towards improving broadband access and adoption throughout the state. Over the past 3 years, Comcast has invested ~$600 million specifically in Indiana’s network infrastructure, which contributed to its broader national investment of over $80 billion in its fiber-rich network across the country over the last decade.
The company already has an impressive technological footprint in Indiana, with an existing 49,000 miles of fiber-rich network infrastructure and over 65,500 WiFi hotspots statewide. Since its launch in 2011, Comcast’s Internet Essentials program, which offers low-cost, high-speed internet and affordable computers to eligible households, has also helped more than 772,000 Indiana residents connect to the internet.
Comcast Corporation (NASDAQ:CMCSA) is a media and technology company that operates through Residential Connectivity & Platforms, Business Services Connectivity, Media, Studios, and Theme Parks segments.
2. Qualcomm Incorporated (NASDAQ:QCOM)
TTM Net Income as of June 13: $11.04 billion
Forward P/E Ratio as of June 13: 13.23
Number of Hedge Fund Holders: 82
Qualcomm Incorporated (NASDAQ:QCOM) is one of the 11 most profitable NASDAQ stocks to buy now. On June 10, the US chipmaker Qualcomm announced the launch of a new AI research and development center in Vietnam. This strategic move aligns with Vietnam’s national strategies for AI, semiconductor development, and digital transformation.
The R&D center will focus on advancing generative and agentic AI solutions. Researchers at the facility will concentrate on developing AI technologies across a broad range of applications, such as smartphones, personal computers, XR (extended reality), automotive systems, and IoT devices.
Qualcomm’s initiative in Vietnam emphasizes several key areas, which include transferring technology, fostering ecosystem collaboration, and building local capacity in the AI & semiconductor sectors. On the same day, Vietnam’s top leader To Lam met with Qualcomm’s President of Global Affairs, Alex Rogers, in Hanoi. During their meeting, To Lam encouraged Qualcomm to continue expanding its operations within the country.
Qualcomm Incorporated (NASDAQ:QCOM) develops and commercializes foundational technologies for the wireless industry worldwide. It operates through 3 segments: Qualcomm CDMA Technologies/QCT, Qualcomm Technology Licensing/QTL, and Qualcomm Strategic Initiatives/QSI.
1. Micron Technology Inc. (NASDAQ:MU)
TTM Net Income as of June 13: $4.67 billion
Forward P/E Ratio as of June 13: 10.87
Number of Hedge Fund Holders: 96
Micron Technology Inc. (NASDAQ:MU) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, Micron Technology announced a substantial investment of ~$200 billion to support its US manufacturing and R&D capabilities. This move aligns with President Donald Trump’s initiative to boost domestic chip production and reduce reliance on foreign manufacturing.
The total investment includes ~$150 billion specifically allocated for domestic manufacturing capacity and another ~$50 billion for R&D. This expanded manufacturing footprint will encompass a second advanced memory fabrication plant in Boise, Idaho (alongside its existing R&D operations), up to 4 leading-edge high-volume fabs in New York, and the expansion & modernization of its existing manufacturing fab in Manassas, Virginia.
A key focus of this investment is to accelerate the development and production of advanced HBM products, which are crucial components in AI data centers. Micron anticipates its initial Idaho plant to begin producing hardware in 2027 and expects to commence ground preparation for its New York facilities later this year. The company aims to produce 40% of its DRAM memory in the US as a result of these investments.
Micron Technology Inc. (NASDAQ:MU) designs, develops, manufactures, and sells memory and storage products internationally. The company operates through 4 segments: Compute & Networking Business Unit, Mobile Business Unit, Embedded Business Unit, and Storage Business Unit.
While we acknowledge the potential of MU to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MU and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
